Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Scientific News
UGA Researchers Discover Potential Treatment for Drug-resistant Tuberculosis
Researchers have developed a new small molecule drug as a treatment against multi-drug resistant tuberculosis.
A Protein's Novel Role In Several Types Of Cancers Discovered
Stanford ChEM-H scientists are helping to develop a novel cancer therapy based on a new finding of a protein that inadvertently promotes cancer growth.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Grant will Help Develop More Powerful Disinfectants
$200,000 grant awarded to develop the next generation of antibacterial cleansers and disinfectants.
Artificially-intelligent Robot Scientist ‘Eve’ Could Boost Search for New Drugs
Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface.
Novogen Announces Important Discovery in Regenerative Medicine Program
A key proof-of-concept step to develop drugs capable of stimulating the function of brain tissue stem cells.
Stanford Chemists Take Step Toward Solving Mystery of How Enzymes Work
Steven Boxer and his students have found that the electrostatic field within an enzyme accounts for the lion's share of its success.
New Class of Synthetic Molecules Mimics Antibodies
A Yale University lab has crafted the first synthetic molecules that have both the targeting and response functions of antibodies.
The Hunt for Botanicals
Herbal medicine can be a double-edged sword and should be more rigorously investigated for both its beneficial and harmful effects, say researchers writing in a special supplement of Science.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Return
Novel Histamine Receptor Family Antagonists by Fragment Screening and Molecular Modelling
Mark Slack, Group Leader Cellular Assays, Evotec, speaking at MedChem Europe
Date Posted: Sunday, June 12, 2011
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
A EUR 1.5 million BMBF grant will advance the H3 receptor antagonist programme through Phase I clinical studies.
Tuesday, April 27, 2010
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Monday, November 09, 2009
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.
Thursday, October 22, 2009
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.
Monday, July 25, 2005
Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration

Thursday, April 10, 2003
Evotec OAI collaboration with KeyNeurotek and IMTM

Wednesday, January 15, 2003
Evotec OAI Names President of Discovery Services

Tuesday, December 10, 2002
Evotec OAI Enters into Agreement With Venture Capital Firm

Thursday, November 14, 2002
 
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters